Curanex Pharmaceuticals Inc

424B4 priced

1,750,000 shares

424B4 priced

8-A12B effective

CERT inactive

EFFECT effective

FWP supplemental

S-1/A amended

Range $4.00 to $6.00 · 3,750,000 shares

FWP supplemental

S-1/A amended

Range $4.00 to $6.00 · 5,500,000 shares

FWP supplemental

S-1/A amended

Price $5.00 · Range $4.00 to $6.00 · 3,750,000 shares

S-1/A amended

Price $5.00 · Range $4.00 to $6.00 · 3,750,000 shares · Gross proceeds $10,000,000

S-1/A amended

Range $4.00 to $6.00 · 3,750,000 shares

S-1/A amended

Price $5.00 · Range $4.00 to $6.00 · 3,750,000 shares · Gross proceeds $10,000,000

S-1 filed

Price $5.00 · Range $4.00 to $6.00 · 3,750,000 shares · Gross proceeds $10,000,000

Curanex Pharmaceuticals Inc. filed an S-1 registration statement for its IPO, disclosing financial details, related party transactions, and recent business developments. The company reported net losses, with a $124,401 loss for the six months ended June 30, 2024. Key events include an asset purchase agreement with Duraviva Pharma Inc., a related party, involving the transfer of intellectual property and 39,000,000 common shares. The company also issued 1,000,000 shares of Series A Preferred Stock, granting 40% voting power. Financial disclosures highlight accrued expenses, lease obligations, and deferred tax assets with full valuation allowances.

DRS/A amended

Curanex Pharmaceuticals Inc. filed a DRS/A on 2024-09-16, detailing financial updates, related party transactions, and recent corporate actions. Key developments include an asset purchase agreement with Duraviva Pharma Inc., a related party, involving the transfer of intellectual property assets and issuance of 39 million common shares. The company also issued 1 million Series A Preferred Stock with 40% voting power. Financials show a net loss of $124,401 for the six months ended June 30, 2024, with significant changes in shareholders' equity due to share issuances and a $69,000 capital contribution. The filing highlights ongoing risks related to related party transactions, impairment losses, and valuation allowances on deferred tax assets.

DRS/A amended

Curanex Pharmaceuticals Inc's recent DRS/A filing highlights significant financial restructuring, including a major asset acquisition from related party Duraviva Pharma Inc. The company reported net losses of $124,401 for the six months ended June 30, 2024, with accrued expenses totaling $600 as of December 31, 2023. The filing details an asset purchase agreement involving $730,000 in consideration and the issuance of 39,000,000 common shares to Duraviva's shareholders. The company also issued Series A Preferred Stock with 40% voting power and disclosed a full valuation allowance on deferred tax assets due to ongoing losses. Recent lease obligations and impairment losses from related party transactions are notable, alongside a lock-up agreement for insiders following the IPO.

DRS filed

Curanex Pharmaceuticals Inc. is conducting an initial public offering (IPO) of its common stock, with Revere Securities LLC acting as the lead underwriter. The offering includes a 180-day lock-up period for insiders and significant shareholders, restricting sales of shares without prior consent. The company has granted the underwriters an option to purchase additional shares (up to 15% of the offering) to cover over-allotments. The offering price will be determined through negotiations, with no guaranteed public market or listing on Nasdaq. The underwriters may engage in price-stabilizing activities, and there are risks related to market volatility and lack of historical trading data.